Alzheimer’s drug has experts divided; rising ...

Australia has many stories from people who say they have long COVID but who are unable to access help | Updated versions of coronavirus vaccines targeting the Omicron variant have been announced, yet the virus still mutates | People with Type 1 diabetes need to monitor their bloo ...  Show more

What an Australian Centre for Disease Control might aim to be; An Indigenous perspective and research to engage culture for protection against cardiovascular disease and stroke; Research on links between mental health and mortality concludes that both mental and physical health c ...  Show more

A new drug for Alzheimer's disease, called lecanemab, got a lot of attention earlier this year for getting fast-tracked approval based on a clinical trial that included nearly 1,800 people. It was the most diverse trial for an Alzheimer's treatment to date, but still not enough t ...  Show more

Following National Alzheimer’s Disease Awareness Month, the CDC shares what physicians and patients need to know about the disease. Lisa McGuire, PhD, lead epidemiologist at the CDC, discusses the importance of catching Alzheimer’s early, its risk factors and barriers to make Alz ...  Show more

After decades without progress, this June a new treatment was approved by the US Food and Drugs Administration - Biogen's Aduhelm. Ivana Davidovic looks into why this process has been so controversial that is now under investigation by a federal watchdog.Aaron Kesselheim, a Harva ...  Show more

Alzheimer's disease is a devastating neurodegenerative condition that affects the entire family. As psychiatrists and psychologists, we often support these patients and their families throughout this entire disease process. With the recent and controversial FDA approval of aducan ...  Show more